nach oben

Erschienen in:

01.04.2008 | Preclinical Studies

NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2

verfasst von: Miguel Muñoz, Marisa Rosso, Francisco J Aguilar, Miguel A González-Moles, Maximino Redondo, Francisco Esteban

Erschienen in: Investigational New Drugs | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Summary

It has been demonstrated that substance P (SP) induces cell proliferation and neurokinin-1 (NK-1) receptor antagonists inhibit growth in several human cancer cell lines, but it is currently unknown whether such actions are exerted on human laryngeal carcinoma cell line HEp-2. In addition, the presence of NK-1 receptor has not been demonstrated in this cell line. We carried out an in vitro study of the growth inhibitory capacity of the NK-1 receptor antagonists L-733,060 and L-732,138 against human laryngeal carcinoma cell line HEp-2. Coulter counter was used to determine viable cell numbers followed by application of the tetrazolium compound MTS. Furthermore, an immunoblot analysis was used to determine the NK-1 receptor, and the 4′,6-diamidino-2-phenylindole (DAPI) method was applied to demonstrate apoptosis of the laryngeal carcinoma cells. We observed the presence of several NK-1 receptors isoforms (34, 46, 58 and 75 kDa). Nanomolar concentrations of SP increased the growth rate of the cell line and micromolar concentrations of L-733,060 and L-732,138 inhibited the growth of the HEp-2 cells in a dose-dependent manner, with and without previous administration of SP. The 50% inhibition concentration values were 21.34 μM and 37.97 (48 h) respectively for HEp-2. NK-1 receptor presence on HEp-2 cells was confirmed by western blotting. DAPI staining revealed the presence of apoptosis following NK-1 receptor antagonists treatment. We demonstrated that NK-1 receptors were present in this laryngeal cancer cell line; these findings demonstrate that SP acts as a mitogen on the human laryngeal carcinoma cell line HEp-2 through the NK-1 receptor, and also indicate that both NK-1 receptors antagonists induced apoptosis of the tumour cells. This new action, reported here for the first time, suggests that the NK-1 receptor is a new and promising target in the treatment of human laryngeal carcinoma.

Entschladen F, Drell TL 4th, Lang K, Joseph J, Zaenker KS (2005) Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invassion and metastasis development. Curr Pharm Des 11:403–411PubMedCrossRef

Muñoz M, Rosso M, Soult JA, Coveñas R (2006) Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV (ed) Brain cancer: therapy and surgical intervention. New York: Nova Science, pp 45–75

von Euler US, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72:74–87

Pernow B (1983) Substance P. Pharmacol Rev 35:85–141PubMed

Hökfelt T, Pernow B, Wahren J (2001) Substance P: a pioneer amongst neuropeptides. J Intern Med 249:27–40PubMedCrossRef

Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56:4983–4991PubMed

Sharif TR, Luo W, Houghron PJ, Sharif M (1996) Substance K peptide induces mitogenesis by activating the mitogen-activated protein kinase signalling pathway through the substance P receptor (NK-1 subtype) in human astrocytoma. Cell Pharmacol 3:441–449

Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 79:236–243PubMed

Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R (2004) Antitumoural action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res 14:183–188PubMedCrossRef

10.

Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39:427–432PubMedCrossRef

11.

Muñoz M, Rosso M, Coveñas R (2006) The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discov 3:323–329CrossRef

12.

Ziche M, Morbidelli L, Pacini M, Gepetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264–278PubMedCrossRef

13.

Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231–238PubMedCrossRef

14.

Harrison T, Willians BJ, Swain CJ, Ball RG (1994) Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Bioorg Med Chem Lett 4:2545–2550CrossRef

15.

Rupniak NM, Carlson E, Boyce S, Webb JK, Hill RG (1996) Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 67:189–195PubMedCrossRef

16.

Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Halle JJ (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640–1645PubMedCrossRef

17.

Varty GB, Cohen-Williams ME, Hunter JC (2003) The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 14:87–95PubMed

18.

Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413–1421PubMedCrossRef

19.

Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G (2003) Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 305:31–39PubMedCrossRef

20.

Woll PJ, Rozengurt E (1988) [D-Arg¹–D-Phe⁵, D-Trp^{7, 9}, Leu¹¹] Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A 35:1859–1863CrossRef

21.

Langdon S, Sethi T, Richie A, Muir M, Smyth J, Rozengurt E (1992) Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52:4554–4557PubMed

22.

Reeve JG, Bleehen NM (1994) [D-Arg¹–D-Phe⁵, D-Trp^{7, 9}, Leu¹¹] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Com 199:1313–1319PubMedCrossRef

23.

Seckl MJ, Higgins T, Wildmer F, Rozengurt E (1997) [D-Arg¹, D-Trp^{5,7, 9}, Leu¹¹] Substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 57:51–54PubMed

24.

Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82:480–487PubMedCrossRef

25.

Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Soult JA, Montero I (2005) Antitumoural action of the neurokinin-1- receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46:2567–2570PubMedCrossRef

26.

Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E (2004) Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 142:105–112PubMed

27.

MacLeod AM, Merchant KJ, Brookfield F, Kelleher F, Stevenson G, Owens AP, Swain CJ, Cascieri MA, Sadowski S, Ber E, Strader CD, Fong TM (1994) Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J Med Chem 37:1269–1274PubMedCrossRef

28.

Cahill CM, Coderre TJ (2002) Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain 95:277–285PubMedCrossRef

29.

Hossen MA, Fujii Y, Sugimoto Y, Kayasuga R, Kamei C (2003) Histamine H3 receptors regulate vascular permeability changes in the skin of mast cell-deficient mice. Int Immunopharmacol 3:1563–1568PubMedCrossRef

30.

Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonists, L-732,138. Invest Ophthalmol Vis Sci 48:2775–2781PubMedCrossRef

31.

Muñoz M, Rosso M, Coveñas R (2007) NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines. In: Fernandes JA (ed) Focus on neuroblastoma research. Nova Science, New York, pp. 31–56

32.

Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R (2003) Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 17:1736–1746PubMedCrossRef

33.

McGillis JP, Organist ML, Scriven KH, Payan DG (1987) Purification of the 33,000-dalton ligand binding-protein constituent of the lymphoblast substance P receptor. J Neurosci Res 18(1):190–194PubMedCrossRef

34.

McGillis JP, Mitsuhashi M, Payan DG (1990) Immunomodulation by tachykinin neuropeptides. Ann N Y Acad Sci 594:85–94PubMedCrossRef

35.

Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731–742PubMed

36.

Tarkkanen A, Tervo T, Tervo K, Eränkö L, Eränkö O, Cuello AC (1983) Substance P immunoreactivity in normal human retina and in retinoblastoma. Ophthalmic Res 15:300–306PubMedCrossRef

37.

Lee CM, Kum W, Cockram CS, Teoh R, Young JD (1989) Functional substance P receptors on a human astrocytoma cell line (U-373 MG). Brain Res 488:328–331PubMedCrossRef

38.

Khare VK, Albino AP, Reed JA (1998) The neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 25:2–10PubMedCrossRef

39.

Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci U S A 97:388–393PubMedCrossRef

40.

Esteban F, Munoz M, González-Moles MA, Rosso M (2006) A role for substance P in carcinogenesis; a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25:137–145PubMedCrossRef

41.

Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533–546PubMedCrossRef

42.

Giardina GAM, Gagliardi S, Martinelli M (2003) Antagonists at the neurokinin receptors—recent patent literature. Drugs 6:758–772

43.

Nowicki M, Miskowiak B (2002) Comparison of the cell immunophenotype of metastatic and primary foci in stage IV-S neuroblastoma. Folia Histochem Cytobiol 40:297–303PubMed

44.

Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792PubMedCrossRef

Titel: NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2
verfasst von: Miguel Muñoz
Marisa Rosso
Francisco J Aguilar
Miguel A González-Moles
Maximino Redondo
Francisco Esteban
Publikationsdatum: 01.04.2008
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 2/2008
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-007-9087-y

Springer Medizin

NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Topical henna for capecitabine induced hand–foot syndrome

Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium

A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie